# US 2022/0033346 A1 · Methods of treating fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033346 A1
- Document ID: US20220033346A1
- Status: Published application
- Kind: A1
- Application number: 17/199,860
- Filed: 2021-03-12
- Published: 2022-02-03
- Earliest claimed: 2012-02-09
- Assignees: Nogra Pharma Limited
- Applicants: Nogra Pharma Limited
- Inventors: Sergio Baroni; Salvatore Bellinvia; Francesca Viti
- Web page: https://patentgrep.com/patent/US20220033346A1

## CPC

- C07C 229/44: with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of treating hepatic fibrosis, the method comprising administering to a patient in need thereof, a therapeutically effective amount of 2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt and/or a stereoisomer thereof.

### Claim 19

A method of treating hepatic fibrosis, the method comprising administering to a patient in need thereof, a pharmaceutical preparation comprising a therapeutically effective amount of 2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt and/or a stereoisomer thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical preparation is administered orally.

### Claim 21 (depends on 19)

The method of claim 19, wherein the patient is human.

### Claim 22 (depends on 19)

The method of claim 19, wherein the 2-methoxy-3-(4′-aminophenyl)propionic acid is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 18)

The method of claim 18, wherein the 2-methoxy-3-(4′-aminophenyl)propionic acid is (S)-2-methoxy-3-(4′-aminophenyl)propionic acid, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 18)

The method of claim 18, wherein the administering is orally.

### Claim 25 (depends on 18)

The method of claim 18, wherein the patient is human.